Clinical Edge Journal Scan

Does Migraine Increase the Risk for Parkinson Disease?


 

Key clinical point: Middle-aged and older women showed no significant association between migraine, and the risk for Parkinson disease (PD), irrespective of migraine subtypes and frequency.

Major findings: Compared to women with without migraine, those with migraine did not show a risk of PD (adjusted hazard ratio [aHR] 1.07; 95% CI 0.88-1.29) irrespective of the presence of aura. No risk was seen even if patients had monthly migraine frequency (aHR 1.09; 95% CI 0.64-1.87), or a weekly or greater migraine frequency (aHR 1.10; 95% CI 0.44-2.75).

Study details: This study involved 39,312 women (age > 45 years) of whom 7321 had migraines, including 2153 with a history of migraine and 5168 with migraine with or without aura. None had a history of PD.

Disclosure: This study was supported by grants from the US National Cancer Institute and the US National Heart, Lung, and Blood Institute. Two authors declared receiving research grants or personal compensation from various sources.

Source: Schulz RS, Glatz T, Buring Jeet al . Migraine and risk of Parkinson disease in women: A cohort study . Neurology. 2024;103(6):e209747 (Aug 21) . doi: 10.1212/WNL.0000000000209747 Source

Recommended Reading

Increasing Daily Steps Predicts Treatment Response to Anti-CGRP Antibodies in Chronic Migraine
Migraine ICYMI
Childhood Abuse Linked to Migraine Risk, Meta-analysis Shows
Migraine ICYMI
Anti-CGRP Antibody Efficacy Unaffected by Chronic Migraine Duration
Migraine ICYMI
History of Abuse May Worsen Disease Burden in Migraine
Migraine ICYMI
Aura Increases Disability in Migraine
Migraine ICYMI
Atogepant Is Effective and Well Tolerated for Migraine Prevention, Irrespective of Dose
Migraine ICYMI
Hypertension Responsible for Detrimental Effects of Leisure Screen Time on Migraine
Migraine ICYMI
Rimegepant Relieves Pain in Acute Migraine
Migraine ICYMI
Commentary: Migraine and Lifestyle Factors, September 2024
Migraine ICYMI
Humanized Monoclonal Antibody Reduces Migraine Frequency in Phase 2 Study
Migraine ICYMI